3,3-二甲基吲哚啉-6-胺 | 179898-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3,3-二甲基吲哚啉-6-胺
• 中文别名: 3,3-二甲基-6-氨基二氢吲哚；6-氨基-3,3-二甲基二氢吲哚
• 英文名称: 6-amino-3,3-dimethylindoline
• 英文别名: 3,3-Dimethylindolin-6-amine；3,3-dimethyl-1,2-dihydroindol-6-amine
• CAS: 179898-73-8
• 化学式: C₁₀H₁₄N₂
• mdl: MFCD11053507
• 分子量: 162.235
• InChiKey: OVSRQUPJJIAWID-UHFFFAOYSA-N

物化性质

• 沸点：
  295.8±39.0 °C(Predicted)
• 密度：
  1.044

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P301 + P312 + P330

反应信息

• 作为反应物：
  描述：

  三氟乙酰乙酸乙酯 、 3,3-二甲基吲哚啉-6-胺 在 zinc(II) chloride 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 3,3-Dimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one
  参考文献：
  名称：

  New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone

  摘要：

  A series of 2(1H)-pyrrolidino [3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00107-3
• 作为产物：
  描述：

  3,3-二甲基吲哚啉 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 5.08h， 生成 3,3-二甲基吲哚啉-6-胺
  参考文献：
  名称：

  New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone

  摘要：

  A series of 2(1H)-pyrrolidino [3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00107-3

文献信息

• Steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05688808A1

  公开（公告）日：1997-11-18

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• Tricyclic steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696130A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• Process for preparing steroid receptor modulator compounds
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US06093821A1

  公开（公告）日：2000-07-25

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了高亲和力、高选择性的非甾体化合物，用于类固醇受体的调节剂。还披露了包含这种化合物的药物组合物，以及使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，还包括在制备这些化合物的中间体和制备类固醇受体调节剂化合物的过程。
• Intermediates for preparation of steroid receptor modulator compounds
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US06121450A1

  公开（公告）日：2000-09-19

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了高亲和力、高选择性的非甾体化合物，用于调节甾体受体。还公开了包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗需要甾体受体激动剂或拮抗剂治疗的患者的方法，还公开了制备这些甾体受体调节剂化合物的中间体和制备过程。
• Methods for the preparation of coumarine derivatives
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：EP1041071A1

  公开（公告）日：2000-10-04

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了对类固醇受体具有高亲和力、高选择性调节作用的非类固醇化合物。还公开了含有此类化合物的药物组合物、使用所公开化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法、制备化合物时有用的中间体以及制备类固醇受体调节剂化合物的工艺。